<?xml version="1.0" encoding="UTF-8"?>
<OAI-PMH xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.openarchives.org/OAI/2.0/ http://www.openarchives.org/OAI/2.0/OAI-PMH.xsd">
  <responseDate>2024-05-03T04:50:56Z</responseDate>
  <request verb="GetRecord" identifier="oai:pubmedcentral.nih.gov:4706696" metadataPrefix="pmc">https:/www.ncbi.nlm.nih.gov/pmc/oai/oai.cgi</request>
  <GetRecord>
    <record>
      <header>
        <identifier>oai:pubmedcentral.nih.gov:4706696</identifier>
        <datestamp>2016-01-10</datestamp>
        <setSpec>trials</setSpec>
        <setSpec>pmc-open</setSpec>
      </header>
      <metadata>
        <article xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xsi:schemaLocation="https://jats.nlm.nih.gov/ns/archiving/1.3/ https://jats.nlm.nih.gov/archiving/1.3/xsd/JATS-archivearticle1-3.xsd" article-type="research-article">
          <front>
            <journal-meta>
              <journal-id journal-id-type="nlm-ta">Trials</journal-id>
              <journal-id journal-id-type="iso-abbrev">Trials</journal-id>
              <journal-title-group>
                <journal-title>Trials</journal-title>
              </journal-title-group>
              <issn pub-type="epub">1745-6215</issn>
              <publisher>
                <publisher-name>BioMed Central</publisher-name>
                <publisher-loc>London</publisher-loc>
              </publisher>
            </journal-meta>
            <article-meta>
              <article-id pub-id-type="accession">PMC4706696</article-id>
              <article-id pub-id-type="pmcid">PMC4706696</article-id>
              <article-id pub-id-type="pmc-uid">4706696</article-id>
              <article-id pub-id-type="pmid">26746195</article-id>
              <article-id pub-id-type="pmid">26746195</article-id>
              <article-id pub-id-type="publisher-id">1142</article-id>
              <article-id pub-id-type="doi">10.1186/s13063-015-1142-y</article-id>
              <article-categories>
                <subj-group subj-group-type="heading">
                  <subject>Study Protocol</subject>
                </subj-group>
              </article-categories>
              <title-group>
                <article-title>Comparative effectiveness of antihypertensive treatment for older children with primary hypertension: study protocol for a series of n-of-1 randomized trials</article-title>
              </title-group>
              <contrib-group>
                <contrib contrib-type="author" corresp="yes">
                  <name>
                    <surname>Samuel</surname>
                    <given-names>Joyce P.</given-names>
                  </name>
                  <address>
                    <phone>713-500-5670</phone>
                    <email>joyce.p.samuel@uth.tmc.edu</email>
                  </address>
                  <xref ref-type="aff" rid="Aff1">1</xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Samuels</surname>
                    <given-names>Joshua A.</given-names>
                  </name>
                  <address>
                    <email>Joshua.A.Samuels@uth.tmc.edu</email>
                  </address>
                  <xref ref-type="aff" rid="Aff1">1</xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Brooks</surname>
                    <given-names>Lauren E.</given-names>
                  </name>
                  <address>
                    <email>Lauren.E.Brooks@uth.tmc.edu</email>
                  </address>
                  <xref ref-type="aff" rid="Aff2">2</xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Bell</surname>
                    <given-names>Cynthia S.</given-names>
                  </name>
                  <address>
                    <email>Cynthia.Bell@uth.tmc.edu</email>
                  </address>
                  <xref ref-type="aff" rid="Aff1">1</xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Pedroza</surname>
                    <given-names>Claudia</given-names>
                  </name>
                  <address>
                    <email>Claudia.Pedroza@uth.tmc.edu</email>
                  </address>
                  <xref ref-type="aff" rid="Aff1">1</xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Molony</surname>
                    <given-names>Donald A.</given-names>
                  </name>
                  <address>
                    <email>Donald.A.Molony@uth.tmc.edu</email>
                  </address>
                  <xref ref-type="aff" rid="Aff3">3</xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Tyson</surname>
                    <given-names>Jon E.</given-names>
                  </name>
                  <address>
                    <email>Jon.E.Tyson@uth.tmc.edu</email>
                  </address>
                  <xref ref-type="aff" rid="Aff1">1</xref>
                </contrib>
                <aff id="Aff1"><label>1</label>Division of Pediatric Nephrology and Hypertension, University of Texas Health Science Center at Houston (UTHealth) McGovern Medical School, 6431 Fannin, MSB 3.121, Houston, Texas 77030 USA </aff>
                <aff id="Aff2"><label>2</label>UTHealth McGovern Medical School, Houston, Texas USA </aff>
                <aff id="Aff3"><label>3</label>Division of Renal Diseases and Hypertension, UTHealth McGovern Medical School, Houston, Texas USA </aff>
              </contrib-group>
              <pub-date pub-type="epub">
                <day>8</day>
                <month>1</month>
                <year>2016</year>
              </pub-date>
              <pub-date pub-type="pmc-release">
                <day>8</day>
                <month>1</month>
                <year>2016</year>
              </pub-date>
              <pub-date pub-type="collection">
                <year>2016</year>
              </pub-date>
              <volume>17</volume>
              <elocation-id>16</elocation-id>
              <history>
                <date date-type="received">
                  <day>27</day>
                  <month>3</month>
                  <year>2015</year>
                </date>
                <date date-type="accepted">
                  <day>22</day>
                  <month>12</month>
                  <year>2015</year>
                </date>
              </history>
              <permissions>
                <copyright-statement>© Samuel et al. 2016</copyright-statement>
                <license license-type="OpenAccess">
                  <license-p><bold>Open Access</bold>This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0/">http://creativecommons.org/licenses/by/4.0/</ext-link>), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/publicdomain/zero/1.0/">http://creativecommons.org/publicdomain/zero/1.0/</ext-link>) applies to the data made available in this article, unless otherwise stated.</license-p>
                </license>
              </permissions>
              <abstract id="Abs1">
                <sec>
                  <title>Background</title>
                  <p>Children are increasingly being diagnosed with primary hypertension. The absence of comparative effectiveness research of antihypertensive medications in children has contributed to considerable differences in prescribing practices among physicians treating children with primary hypertension. Even if parallel-group trials had established a best overall choice for most of these children, the best medication for an individual may differ from the best overall medication.</p>
                </sec>
                <sec>
                  <title>Methods/design</title>
                  <p>This project consists of a series of systematically administered n-of-1 trials among older children to verify the need for ongoing antihypertensive treatment and, if so, to identify the preferred single drug therapy from among the three major classes of drugs commonly used for primary hypertension (angiotensin-converting enzyme inhibitors, calcium channel blockers, and diuretics). We will determine whether one of these is the preferred therapy for the great majority of patients. The “preferred” therapy is the drug which produces normal ambulatory blood pressure, with the greatest reduction in blood pressure without unacceptable side effects. We will recruit 50 patients from the Houston Pediatric and Adolescent Hypertension Program clinic. For each patient, the three drugs will be prescribed in random order and each drug will be taken for 2 weeks. The effectiveness of each therapy will be measured with 24-h ambulatory blood pressure monitoring, and tolerability will be assessed using a side effect questionnaire. Participants will rotate through treatment periods, repeating drugs and adjusting doses until the preferred therapy is identified. In assessing whether one of the medications is most effective for the majority of subjects, the primary outcome will be the percentage of participants for whom each drug is selected as the preferred therapy. We hypothesize that no drug will be selected for the great majority of the subjects, a finding that would support consideration of clinical use of n-of-1 trials. Secondary analyses will explore whether patient characteristics predict which medication will be selected as a preferred drug.</p>
                </sec>
                <sec>
                  <title>Discussion</title>
                  <p>This study will help optimize care of participating patients and provide evidence regarding the usefulness of n-of-1 trials in identifying appropriate treatment for children with hypertension and potentially other disorders.</p>
                </sec>
                <sec>
                  <title>Trial registration</title>
                  <p>Clinicaltrials.gov <ext-link ext-link-type="uri" xlink:href="https://clinicaltrials.gov/show/NCT02412761">NCT02412761</ext-link> (registered 4/8/2015).</p>
                </sec>
              </abstract>
              <kwd-group xml:lang="en">
                <title>Keywords</title>
                <kwd>Antihypertensive medications</kwd>
                <kwd>N-of-1 trial</kwd>
                <kwd>Pediatrics</kwd>
                <kwd>Hypertension</kwd>
                <kwd>Comparative effectiveness research</kwd>
              </kwd-group>
              <custom-meta-group>
                <custom-meta>
                  <meta-name>issue-copyright-statement</meta-name>
                  <meta-value>© The Author(s) 2016</meta-value>
                </custom-meta>
              </custom-meta-group>
            </article-meta>
          </front>
          <body>
            <sec id="Sec1" sec-type="introduction">
              <title>Background</title>
              <p>Hypertension is one of the most important modifiable risk factors for adverse health outcomes: premature death, renal failure, stroke, and myocardial infarction are each reduced when blood pressure is controlled [<xref ref-type="bibr" rid="CR1">1</xref>–<xref ref-type="bibr" rid="CR8">8</xref>]. Hypertension is increasingly diagnosed in children, and effective treatment will be particularly important to reduce the ultimate years of healthy life lost to these problems.</p>
              <p>Unfortunately, only sparse data from clinical trials inform the use of different antihypertensive agents in children [<xref ref-type="bibr" rid="CR9">9</xref>]. As a result, the best first-line therapy for children has not been defined for national guidelines [<xref ref-type="bibr" rid="CR10">10</xref>], and clinical practice is highly variable [<xref ref-type="bibr" rid="CR11">11</xref>–<xref ref-type="bibr" rid="CR13">13</xref>]. In a survey of North American pediatric nephrologists, 47 % chose angiotensin-converting enzyme (ACE) inhibitors; 37 %, calcium channel blockers, and 15 % diuretics as initial therapy in children with primary hypertension [<xref ref-type="bibr" rid="CR14">14</xref>].</p>
              <p>Large parallel-group randomized clinical trials (RCTs) are generally required to determine which therapy is the preferred initial therapy that on average has the greatest overall benefit. However, that therapy may be ineffective or harmful for some patients [<xref ref-type="bibr" rid="CR15">15</xref>]. Parallel-group RCTs are often far underpowered to identify important subgroup differences or treatment interactions needed to distinguish such patients [<xref ref-type="bibr" rid="CR16">16</xref>]. Additionally, subgroup analyses cannot unravel the complex interplay between multiple characteristics that are simultaneously at work within a given individual to modify the treatment effect [<xref ref-type="bibr" rid="CR17">17</xref>].</p>
              <p>In some circumstances the best treatment for individual patients may be identified in n-of-1 trials. Such trials are systematically administered, single patient RCTs in which the patient serially receives multiple therapies in a random order [<xref ref-type="bibr" rid="CR18">18</xref>]. These trials can include allocation concealment, blinding, and all other features used to minimize bias in traditional parallel-group RCTs [<xref ref-type="bibr" rid="CR19">19</xref>]. Unlike traditional RCTs, n-of-1 trials can facilitate treatment recommendations for each individual patient based on his or her responses to the different therapies [<xref ref-type="bibr" rid="CR20">20</xref>]. N-of-1 trials provide a formal and more rigorous assessment than the informal “trial of therapy” often used clinically in prescribing an antihypertensive agent—an approach that can be biased due to inaccurate or infrequent assessments of blood pressure, failure to assess more than one medication, absence of predefined criteria for success, and physician reluctance to change therapy. By involving patients and their families in verifying the presence of hypertension and identifying the preferred therapy, n-of-1 trials might reduce unnecessary treatment and increase adherence when treatment is needed [<xref ref-type="bibr" rid="CR21">21</xref>–<xref ref-type="bibr" rid="CR23">23</xref>].</p>
              <p>Guyatt and colleagues, who pioneered n-of-1 trials, have described the conditions for which they are most useful [<xref ref-type="bibr" rid="CR24">24</xref>]. The condition should be chronic and require prolonged treatment; the therapies should have a rapid onset and offset of action; the response to treatment should be accurately measurable; and the physician should be willing to consider multiple therapies. Such trials have been performed in a variety of conditions, including chronic obstructive lung disease, osteoarthritis, neuropathic pain, palliative care, traumatic brain injury, and attention deficit-hyperactivity disorder [<xref ref-type="bibr" rid="CR25">25</xref>–<xref ref-type="bibr" rid="CR30">30</xref>]. The treatment of primary hypertension in children meets these criteria and is equally well suited for an n-of-1 trial.</p>
            </sec>
            <sec id="Sec2" sec-type="materials|methods">
              <title>Methods</title>
              <p>This is a series of n-of-1 trials to compare the effectiveness and tolerability of lisinopril, amlodipine, and hydrochlorothiazide within each patient. Each of these therapies has previously been proven to be efficacious in blinded placebo-controlled RCTs [<xref ref-type="bibr" rid="CR31">31</xref>–<xref ref-type="bibr" rid="CR33">33</xref>]. The preferred therapy for each patient is defined a priori as the medication which yields normal ambulatory blood pressure (BP), with the greatest reduction in ambulatory wake mean systolic BP compared to baseline BP and without the presence of unacceptable side effects. Each n-of-1 trial consists of a series of 2-week treatment periods which are repeated until the preferred therapy is identified (Fig. <xref rid="Fig1" ref-type="fig">1</xref>). Once the trial is complete, the patient resumes usual care in the Pediatric Hypertension Clinic.<fig id="Fig1"><label>Fig. 1</label><caption><p>N-of-1 design schema</p></caption><graphic xlink:href="13063_2015_1142_Fig1_HTML" id="MO1"/></fig></p>
              <sec id="Sec3">
                <title>Study objectives and hypothesis</title>
                <p>The primary objective is to determine whether there are individual differences in the response to different drug classes. We hypothesize that no drug will be selected for 80 % or more of the participants, a finding that might prompt consideration of n-of-1 trials in clinical practice before selecting a therapy for long-term administration. The secondary objective is to explore whether there are baseline characteristics associated with the choice of the preferred therapy for each patient.</p>
              </sec>
              <sec id="Sec4">
                <title>Study setting, eligibility criteria, and recruitment</title>
                <p>This study is located in Houston, Texas, with recruitment occurring from patients attending the Houston Pediatric and Adolescent Hypertension Program (HPAHP) clinic at the University of Texas Health Science Center at Houston (UTHealth). Patients receiving pharmacologic antihypertensive therapy or recently referred patients who meet criteria for treatment based on ambulatory blood pressure monitoring (ABPM) are invited to participate if they are aged 9–22 years and have primary hypertension. Patients less than 9 years old are not included because younger patients have a higher likelihood of secondary hypertension, and would be less likely to comply with the repeated ABPMs required for the n-of-1 trial. All patients in this clinic undergo evaluation for secondary causes of hypertension based on national guidelines [<xref ref-type="bibr" rid="CR10">10</xref>]. Only those patients without a compelling indication to select one particular medication (such as choosing ACE inhibitors or angiotensin receptor blockers in patients with diabetes) are considered eligible for participation. Patients with a specific contraindication for any of the three therapies are excluded.</p>
                <p>The n-of-1 trial is offered to all eligible patients as an optional program. Patients are informed that participation is voluntary, and they can withdraw at any time. Verbal informed consent is obtained from each participant.</p>
              </sec>
              <sec id="Sec5">
                <title>Blinding and randomization</title>
                <p>We have made no attempt to alter the medications to make them identical and indistinguishable to the patients, partly because of feasibility, cost, and concern that their effects in clinical practice might be inadvertently altered. During the n-of-1 trial, when comparing the effectiveness and tolerability of each therapy with the family, the physician is blinded to which drug was tested in each time period by using a summary sheet of ABPM results and side effects which refers to treatments as first, second, or third used. The order of the medications given is randomized each time they are compared for a patient using an online random number generator [<xref ref-type="bibr" rid="CR34">34</xref>].</p>
              </sec>
              <sec id="Sec6">
                <title>Blood pressure definitions</title>
                <p>Ambulatory hypertension is defined as the combination of 1) wake or sleep mean ambulatory systolic blood pressure (SBP) or diastolic blood pressure (DBP) greater than the height-sex referenced 95<sup>th</sup> percentile and 2) BP load &gt; 25 %, based on standardized values from the 2014 American Heart Association Scientific Statement on pediatric ABPM [<xref ref-type="bibr" rid="CR35">35</xref>]. For patients aged ≥ 18 years, ambulatory hypertension is defined by adult criteria [<xref ref-type="bibr" rid="CR36">36</xref>].</p>
                <p>Normal ambulatory blood pressure is defined as both wake and sleep mean ambulatory SBP and DBP less than the height-sex referenced 95<sup>th</sup> percentile.</p>
              </sec>
              <sec id="Sec7">
                <title>N-of-1 trial design</title>
                <sec id="Sec8">
                  <title>Establish baseline blood pressure</title>
                  <p>Baseline BP is defined as the wake mean SBP on the most recent 24-h ambulatory blood pressure monitoring (ABPM) off antihypertensive therapy. If it has been over a year since the last ABPM off therapy, the n-of-1 trial begins with a washout of previous antihypertensive therapy for at least 2 weeks followed by a repeat ABPM to confirm the need for ongoing therapy and to establish the baseline BP.</p>
                </sec>
                <sec id="Sec9">
                  <title>Treatment cycles</title>
                  <p>The medications are prescribed in random order at typical starting weight-based doses (Table <xref rid="Tab1" ref-type="table">1</xref>). The first week of each 2-week treatment period is considered a washout period, in which the effects of the previous treatment are expected to diminish and the effects of the current treatment commence [<xref ref-type="bibr" rid="CR37">37</xref>–<xref ref-type="bibr" rid="CR39">39</xref>]. No assessment of BP reduction is taken during the washout period. At the end of the second week (day 13–14), ABPM is performed for a 24-h period with readings every 30 min (using SpaceLabs Ultralite 90217 monitors, SpaceLabs, Inc., Issaquah, WA, USA).<table-wrap id="Tab1"><label>Table 1</label><caption><p>Dose adjustment plan</p></caption><table frame="hsides" rules="groups"><thead><tr><th/><th>Initial dose</th><th>Dosing adjustment</th><th>Maximum dose</th></tr></thead><tbody><tr><td>Amlodipine</td><td>0.1 mg/kg/dose Qday (max 5 mg/day)</td><td>Double dose</td><td>10 mg/day</td></tr><tr><td>Hydrochlorothiazide</td><td>1 mg/kg/dose Qday (max 25 mg/day)</td><td>Double dose</td><td>50 mg/day or 3 mg/kg/day</td></tr><tr><td>Lisinopril</td><td>0.1 mg/kg/dose Qday (max 10 mg/day)</td><td>Double dose</td><td>40 mg/day or 0.6 mg/kg/day</td></tr></tbody></table></table-wrap></p>
                  <p>A clinic visit is completed on day 14 of each 2-week treatment period. At this visit, clinic BP is measured using standard methodology [<xref ref-type="bibr" rid="CR10">10</xref>] with an oscillometric device (Spot Vital Signs LXi, Welch Allyn, Skaneateles Falls, NY, USA [<xref ref-type="bibr" rid="CR40">40</xref>]) for four repeated seated measurements. In addition, at each visit the patient is weighed, interim medical history is obtained, side effects are assessed using a questionnaire, pill count is performed, ABPM activity diary is confirmed, and ABPM data is downloaded.</p>
                  <p>Cycle 1 is defined as the initial 6 weeks of treatment periods, during which the three options are assessed for 2 weeks each (Fig. <xref rid="Fig1" ref-type="fig">1</xref>). At the clinic visit marking the end of Cycle 1, the physician, patient, and parents discuss the comparative effectiveness and tolerability of each of the tested options. The drug that produces either an unacceptable side effect or the smallest decrease in ambulatory wake SBP will be removed from consideration. The remaining two drugs are repeated for 2-week treatment periods (Cycle 2) in random order to confirm which drug yields the greatest reduction in BP without unacceptable side effects. If normal ambulatory blood pressure is achieved in Cycle 1 with either of the two drugs to be repeated, the doses are not changed for Cycle 2. If ambulatory hypertension persists in Cycle 1 on all tested therapies, the doses for the medications are increased for the subsequent treatment periods according to a preplanned protocol (Table <xref rid="Tab1" ref-type="table">1</xref>).</p>
                </sec>
                <sec id="Sec10">
                  <title>Trial conclusion</title>
                  <p>The trial is concluded after a drug has been shown to produce normal ambulatory BP on at least two treatment periods without unacceptable side effects. If more than one drug meets these criteria, the physician and the family employ shared decision making to determine the final preferred therapy, based on greatest average reduction in wake BP or side effect experience. If the patient or family chooses to withdraw from the n-of-1 trial before Cycle 2 can be completed, the data from Cycle 1 is used to determine the preferred drug. If none of the treatments result in normal ambulatory BP despite maximal doses, the trial is concluded and the patient returns to usual care at the Pediatric Hypertension Clinic to begin a combination therapy.</p>
                </sec>
              </sec>
              <sec id="Sec11">
                <title>Patient measures</title>
                <sec id="Sec12">
                  <title>Ambulatory BP monitoring</title>
                  <p>We use ABPM instead of clinic BP measurements to assess BP reduction on treatment for several reasons. Multiple measurements are obtained with each 24-h reading, resulting in reduced variability and greater reproducibility of measurements compared to office BP readings [<xref ref-type="bibr" rid="CR41">41</xref>–<xref ref-type="bibr" rid="CR45">45</xref>]. This provides greater precision in our ability to discriminate between the effects of each drug within a single patient. ABPM allows for blinded collection of BP measurements. ABPM eliminates the white-coat effect, which may vary by antihypertensive drug class [<xref ref-type="bibr" rid="CR46">46</xref>]. ABPM has been shown to be an important tool in evaluating the efficacy of BP medications in adults [<xref ref-type="bibr" rid="CR47">47</xref>, <xref ref-type="bibr" rid="CR48">48</xref>], in discriminating the comparative effectiveness of different antihypertensive drugs in adults [<xref ref-type="bibr" rid="CR49">49</xref>, <xref ref-type="bibr" rid="CR50">50</xref>], and has been suggested as a superior measurement tool in hypertensive children [<xref ref-type="bibr" rid="CR41">41</xref>, <xref ref-type="bibr" rid="CR51">51</xref>].</p>
                </sec>
                <sec id="Sec13">
                  <title>Side effects</title>
                  <p>A side effect questionnaire has been developed for this project to identify unacceptable side effects (Fig. <xref rid="Fig2" ref-type="fig">2</xref>). The questionnaire includes an open-ended prompt to list all unpleasant effects from the medication, with a rating scale for how bothersome the effect is and whether it is considered unacceptable. The questionnaire was piloted in a sample group of adolescent patients in our clinic. We used the technique of translation with back-translation to create a Spanish language version of the questionnaire.<fig id="Fig2"><label>Fig. 2</label><caption><p>Side effect questionnaire</p></caption><graphic xlink:href="13063_2015_1142_Fig2_HTML" id="MO2"/></fig></p>
                </sec>
                <sec id="Sec14">
                  <title>Safety and adverse events</title>
                  <p>If the patient takes either lisinopril or hydrochlorothiazide for the first time during the course of the n-of-1 trial, blood monitoring is performed two weeks after starting the medication as per usual clinical practice. If laboratory testing shows abnormal chemistry (excessive change in serum creatinine or potassium levels), then that treatment will be removed from consideration as a preferred drug. BP will be checked in clinic and in the ambulatory setting every two weeks. If BP on a particular treatment is considered by the physician to be dangerously high or low for that patient, the drug will not be repeated.</p>
                </sec>
                <sec id="Sec15">
                  <title>Demographic data and baseline characteristics</title>
                  <p>For all participants, at the first visit we collect information on patient age, gender, weight, height, body-mass index, race/ethnicity, self-reported exercise activity (number of hours of exercise in a usual week), and insurance coverage. We also collect parental data on age, marital status, total number of children in the household, race/ethnicity, employment, and educational attainment.</p>
                </sec>
              </sec>
              <sec id="Sec16">
                <title>Adherence to study procedures</title>
                <p>We anticipate that the extra effort required to participate in the n-of-1 trial compared to usual care (frequent clinic visits and the repeated use of 24-h ABPM) will deter some families from participation. In order to maximize adherence, we utilize concepts derived from motivational interviewing, using an empathetic approach to help families explore and resolve the potential hindrances to compliance with study procedures before they begin the n-of-1 trial. We also provide external motivation with financial incentives to the patient, offering gift cards in gradually increasing amounts (ranging from $15–$40 per card) for each adequate ABPM reading to motivate the participants to comply with repeated ABPMs as they progress through the n-of-1 trial. An adequate ABPM study must contain at least 18 h of measurements.</p>
                <p>We expect that some families might find it difficult to present to our clinic during regular office hours for visits every 2 weeks. With that in mind, for all visits associated with the n-of-1 trial, we offer extended office hours and validated parking, and we do not charge patients or insurance companies for the visits or ABPM interpretation.</p>
                <p>Adherence to the prescribed therapy is determined using a pill count at each visit. Percent adherence is calculated as ([number of pills taken] ÷ [number of pills expected to have been taken]) × 100.</p>
                <sec id="Sec17">
                  <title>Acceptability questionnaire</title>
                  <p>At the final visit, participants complete a survey to assess the acceptability of the n-of-1 trial. Questions are asked on a four-point response scale, addressing whether the monetary incentives (gift cards and parking validations) influenced their willingness to participate. Open-ended questions explore the importance of after-hour options and the most satisfying and most difficult aspects of the n-of-1 trial.</p>
                </sec>
              </sec>
              <sec id="Sec18">
                <title>Power calculation and analytic plan</title>
                <p>The aggregate data from all completed n-of-1 trials will be combined to assess the primary outcome, which is the percentage of patients for whom each drug is selected as the preferred therapy. For our primary aim of determining if any drug will be selected for 80 % or more of the subjects, a frequentist approach will be used to calculate for each drug a point estimate and 95 % binomial confidence interval for the proportion of individuals who prefer that drug. Our primary hypothesis of treatment equipoise will be confirmed if the upper limit of the 95 % confidence interval does not reach 80 % for any of the drugs (that is, the observed proportion of individuals who prefer any one drug will be less than 80 %).</p>
                <p>With the expectation of recruitment of 75 subjects (2 to 3 per month) and 33 % drop-out rate, we expect to conduct 50 separate n-of-1 trials over the course of the funding period. With this number of patients our power (at an alpha error of 0.05) to reject our hypothesis is estimated to be ≥ 80 % if in truth any drug is preferred by 60 % or fewer study patients, as this would produce a 95 % confidence interval which does not reach 80 %.</p>
                <p>We anticipate that routine use of n-of-1 trials might be considered for use in clinical practice if there is no drug that is preferred for ≥ 80 % of patients needing treatment. If no drug is preferred for a high proportion of patients, we will also conduct exploratory analyses to predict which drug is most likely to be preferred for individual patients based on their baseline characteristics (race/ethnicity, gender, age, physical activity). These analyses will be conducted using hierarchical logistic models including the baseline covariates as predictors and subject-specific random effects (to account for within-subject correlation).</p>
                <p>We will also employ a Bayesian approach to analysis. Prior probabilities that any drug will be selected as a preferred drug are completely uninformed, given the lack of previous head-to-head comparisons of antihypertensive drugs in children. Each drug will be assigned a prior probability of 33 % (with 95 % credible intervals 10–90 %) to be selected as a preferred drug. We will update the overall probabilities after all n-of-1 trials are complete, and report point estimate and credible intervals for the primary outcome. We will calculate the probability that this proportion is &gt; 80 %. Assuming a prior probability of 33 % and a sample size of 50, if the true rate of drug A being a preferred drug is 60 %, we will have ≥ 90 % power to reject our primary hypothesis.</p>
                <p>In short, we will have sufficient sample size to determine if a single drug is preferred by the overwhelming majority of patients.</p>
              </sec>
              <sec id="Sec19">
                <title>Data management</title>
                <p>Study data is managed using REDCap (Research Electronic Data Capture) hosted at UTHealth [<xref ref-type="bibr" rid="CR52">52</xref>]. REDCap is a secure, web-based application designed to support data capture for multiple purposes, including research and quality improvement.</p>
              </sec>
              <sec id="Sec20">
                <title>Ethics approval</title>
                <p>The Committee for the Protection of Human Subjects at the UTHealth McGovern Medical School assessed the study protocol and determined that formal approval was not required, as they considered the proposal likely to reduce patient risk and classified this study as a quality improvement project (HSC-MS-13-0287). Verbal informed consent is obtained from all participants. Patients are made aware that their participation is voluntary, and they can withdraw at any time. The question of whether n-of-1 trials should be considered clinical care, quality improvement, and/or research has been discussed elsewhere [<xref ref-type="bibr" rid="CR53">53</xref>]. Traditional distinctions between patient care and quality improvement initiatives have been seriously questioned with a growing belief that the important issue is whether patient risk is increased relative to usual patient care [<xref ref-type="bibr" rid="CR54">54</xref>, <xref ref-type="bibr" rid="CR55">55</xref>]. Since each therapy tested in the n-of-1 trials is commonly used in routine clinical practice for the treatment of hypertension in children, we do not expect any additional risk to the participants relative to usual patient care. This series of n-of-1 trials is designed to optimize individual patient care in our center, although we expect some generalizable insights to result from our data.</p>
              </sec>
            </sec>
            <sec id="Sec21" sec-type="discussion">
              <title>Discussion</title>
              <p>As more children are prescribed antihypertensive therapy for primary hypertension, the need for comparative effectiveness data on the therapeutic options has become more pressing. N-of-1 trials provide physicians with this data from their own patients, allowing the objective evaluation of potentially beneficial therapies while minimizing bias, reducing the time spent on therapies which do not work for that patient, and resolving therapeutic uncertainty much faster than usual care.</p>
              <sec id="Sec22">
                <title>Trial status</title>
                <p>The study opened to recruitment in June 2013, with recruitment expected to end in December 2015. The future reports from this study will follow the CONSORT extension for reporting n-of-1 trials (CENT) [<xref ref-type="bibr" rid="CR56">56</xref>].</p>
              </sec>
            </sec>
          </body>
          <back>
            <glossary>
              <title>Abbreviations</title>
              <def-list>
                <def-item>
                  <term>ABPM</term>
                  <def>
                    <p>ambulatory blood pressure monitoring</p>
                  </def>
                </def-item>
                <def-item>
                  <term>ACE</term>
                  <def>
                    <p>angiotensin-converting enzyme</p>
                  </def>
                </def-item>
                <def-item>
                  <term>BP</term>
                  <def>
                    <p>blood pressure</p>
                  </def>
                </def-item>
                <def-item>
                  <term>DBP</term>
                  <def>
                    <p>diastolic blood pressure</p>
                  </def>
                </def-item>
                <def-item>
                  <term>HPAHP</term>
                  <def>
                    <p>Houston Pediatric and Adolescent Hypertension Program</p>
                  </def>
                </def-item>
                <def-item>
                  <term>RCT</term>
                  <def>
                    <p>randomized clinical trial</p>
                  </def>
                </def-item>
                <def-item>
                  <term>SBP</term>
                  <def>
                    <p>systolic blood pressure</p>
                  </def>
                </def-item>
              </def-list>
            </glossary>
            <fn-group>
              <fn>
                <p>
                  <bold>Competing interests</bold>
                </p>
                <p>The authors declare that they have no competing interests.</p>
              </fn>
              <fn>
                <p>
                  <bold>Authors’ contributions</bold>
                </p>
                <p>JPS is the principal investigator for the study, conceived the study, wrote the manuscript, and secured funding for the project. JAS, DM, and JT contributed to the study design and critically revised the manuscript. CB and CP provided statistical advice and contributed to the writing of the manuscript. LB assisted with study procedures and contributed to the writing of the manuscript. All authors read and approved the final manuscript.</p>
              </fn>
            </fn-group>
            <ack>
              <title>Acknowledgements</title>
              <p>We thank the Center for Clinical and Translational Sciences at UTHealth for support of REDCap. We thank Robert Morgan, Ph.D. at the UTHealth School of Public Health for his guidance in the creation of the side effect questionnaire, and Angela Stotts, Ph.D. and Thomas Northrup, Ph.D. at the UTHealth McGovern Medical School Department of Family and Community Medicine for their assistance in the development of motivational techniques to improve adherence to study procedures.</p>
              <sec id="FPar1">
                <title>Funding</title>
                <p>This work is supported by a Career Development Award (KL2) awarded to Joyce Samuel by the Center for Clinical and Translational Sciences at UTHealth, which is funded by NIH Clinical and Translational Award 5KL2 TR000370 for the KL2 program from the National Center for Advancing Translational Sciences. The funding body had no role in the writing of the manuscript or in the decision to submit the manuscript for publication.</p>
              </sec>
            </ack>
            <ref-list id="Bib1">
              <title>References</title>
              <ref id="CR1">
                <label>1.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Devereux</surname>
                      <given-names>RB</given-names>
                    </name>
                    <name>
                      <surname>Wachtell</surname>
                      <given-names>K</given-names>
                    </name>
                    <name>
                      <surname>Gerdts</surname>
                      <given-names>E</given-names>
                    </name>
                    <name>
                      <surname>Boman</surname>
                      <given-names>K</given-names>
                    </name>
                    <name>
                      <surname>Nieminen</surname>
                      <given-names>MS</given-names>
                    </name>
                    <name>
                      <surname>Papademetriou</surname>
                      <given-names>V</given-names>
                    </name>
                    <etal/>
                  </person-group>
                  <article-title>Prognostic significance of left ventricular mass change during treatment of hypertension</article-title>
                  <source>JAMA</source>
                  <year>2004</year>
                  <volume>292</volume>
                  <issue>19</issue>
                  <fpage>2350</fpage>
                  <lpage>6</lpage>
                  <pub-id pub-id-type="doi">10.1001/jama.292.19.2350</pub-id>
                  <?supplied-pmid 15547162?>
                  <pub-id pub-id-type="pmid">15547162</pub-id>
                </element-citation>
              </ref>
              <ref id="CR2">
                <label>2.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Gerdts</surname>
                      <given-names>E</given-names>
                    </name>
                    <name>
                      <surname>Cramariuc</surname>
                      <given-names>D</given-names>
                    </name>
                    <name>
                      <surname>de Simone</surname>
                      <given-names>G</given-names>
                    </name>
                    <name>
                      <surname>Wachtell</surname>
                      <given-names>K</given-names>
                    </name>
                    <name>
                      <surname>Dahlöf</surname>
                      <given-names>B</given-names>
                    </name>
                    <name>
                      <surname>Devereux</surname>
                      <given-names>RB</given-names>
                    </name>
                  </person-group>
                  <article-title>Impact of left ventricular geometry on prognosis in hypertensive patients with left ventricular hypertrophy (the LIFE study)</article-title>
                  <source>Eur J Echocardiogr</source>
                  <year>2008</year>
                  <volume>9</volume>
                  <issue>6</issue>
                  <fpage>809</fpage>
                  <lpage>15</lpage>
                  <pub-id pub-id-type="doi">10.1093/ejechocard/jen155</pub-id>
                  <?supplied-pmid 18490279?>
                  <pub-id pub-id-type="pmid">18490279</pub-id>
                </element-citation>
              </ref>
              <ref id="CR3">
                <label>3.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Ibsen</surname>
                      <given-names>H</given-names>
                    </name>
                    <name>
                      <surname>Olsen</surname>
                      <given-names>MH</given-names>
                    </name>
                    <name>
                      <surname>Wachtell</surname>
                      <given-names>K</given-names>
                    </name>
                    <name>
                      <surname>Borch-Johnsen</surname>
                      <given-names>K</given-names>
                    </name>
                    <name>
                      <surname>Lindholm</surname>
                      <given-names>LH</given-names>
                    </name>
                    <name>
                      <surname>Mogensen</surname>
                      <given-names>CE</given-names>
                    </name>
                    <etal/>
                  </person-group>
                  <article-title>Reduction in albuminuria translates to reduction in cardiovascular events in hypertensive patients: losartan intervention for endpoint reduction in hypertension study</article-title>
                  <source>Hypertension</source>
                  <year>2005</year>
                  <volume>45</volume>
                  <issue>2</issue>
                  <fpage>198</fpage>
                  <lpage>202</lpage>
                  <pub-id pub-id-type="doi">10.1161/01.HYP.0000154082.72286.2a</pub-id>
                  <?supplied-pmid 15655123?>
                  <pub-id pub-id-type="pmid">15655123</pub-id>
                </element-citation>
              </ref>
              <ref id="CR4">
                <label>4.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Larstorp</surname>
                      <given-names>AC</given-names>
                    </name>
                    <name>
                      <surname>Okin</surname>
                      <given-names>PM</given-names>
                    </name>
                    <name>
                      <surname>Devereux</surname>
                      <given-names>RB</given-names>
                    </name>
                    <name>
                      <surname>Olsen</surname>
                      <given-names>MH</given-names>
                    </name>
                    <name>
                      <surname>Ibsen</surname>
                      <given-names>H</given-names>
                    </name>
                    <name>
                      <surname>Dahlöf</surname>
                      <given-names>B</given-names>
                    </name>
                    <etal/>
                  </person-group>
                  <article-title>Regression of ECG-LVH is associated with lower risk of new-onset heart failure and mortality in patients with isolated systolic hypertension. The LIFE study</article-title>
                  <source>Am J Hypertens.</source>
                  <year>2012</year>
                  <volume>25</volume>
                  <issue>10</issue>
                  <fpage>1101</fpage>
                  <lpage>9</lpage>
                  <pub-id pub-id-type="doi">10.1038/ajh.2012.86</pub-id>
                  <?supplied-pmid 22717544?>
                  <pub-id pub-id-type="pmid">22717544</pub-id>
                </element-citation>
              </ref>
              <ref id="CR5">
                <label>5.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Turnbull</surname>
                      <given-names>F</given-names>
                    </name>
                  </person-group>
                  <article-title>Blood Pressure Lowering Treatment Trialists C. Effects of different blood-pressure-lowering regimens on major cardiovascular events: results of prospectively-designed overviews of randomised trials</article-title>
                  <source>Lancet</source>
                  <year>2003</year>
                  <volume>362</volume>
                  <issue>9395</issue>
                  <fpage>1527</fpage>
                  <lpage>35</lpage>
                  <pub-id pub-id-type="doi">10.1016/S0140-6736(03)14739-3</pub-id>
                  <?supplied-pmid 14615107?>
                  <pub-id pub-id-type="pmid">14615107</pub-id>
                </element-citation>
              </ref>
              <ref id="CR6">
                <label>6.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <collab>SHEP Cooperative Research Group</collab>
                  </person-group>
                  <article-title>Prevention of stroke by antihypertensive drug treatment in older persons with isolated systolic hypertension. Final results of the Systolic Hypertension in the Elderly Program (SHEP)</article-title>
                  <source>JAMA</source>
                  <year>1991</year>
                  <volume>265</volume>
                  <issue>24</issue>
                  <fpage>3255</fpage>
                  <lpage>64</lpage>
                  <pub-id pub-id-type="doi">10.1001/jama.1991.03460240051027</pub-id>
                  <pub-id pub-id-type="pmid">2046107</pub-id>
                </element-citation>
              </ref>
              <ref id="CR7">
                <label>7.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <collab>Hypertension Detection and Follow-up Program Cooperative Group</collab>
                  </person-group>
                  <article-title>Five-year findings of the hypertension detection and follow-up program. I. Reduction in mortality of persons with high blood pressure, including mild hypertension</article-title>
                  <source>JAMA</source>
                  <year>1979</year>
                  <volume>242</volume>
                  <issue>23</issue>
                  <fpage>2562</fpage>
                  <lpage>71</lpage>
                  <pub-id pub-id-type="doi">10.1001/jama.1979.03300230018021</pub-id>
                  <pub-id pub-id-type="pmid">490882</pub-id>
                </element-citation>
              </ref>
              <ref id="CR8">
                <label>8.</label>
                <mixed-citation publication-type="other">Veterans Administration Cooperative Study Group on Antihypertensive Agents. Effects of treatment on morbidity in hypertension. II. Results in patients with diastolic blood pressure averaging 90 through 114 mm Hg. JAMA. 1970;213(7):1143–52.</mixed-citation>
              </ref>
              <ref id="CR9">
                <label>9.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Chaturvedi</surname>
                      <given-names>S</given-names>
                    </name>
                    <name>
                      <surname>Lipszyc</surname>
                      <given-names>DH</given-names>
                    </name>
                    <name>
                      <surname>Licht</surname>
                      <given-names>C</given-names>
                    </name>
                    <name>
                      <surname>Craig</surname>
                      <given-names>JC</given-names>
                    </name>
                    <name>
                      <surname>Parekh</surname>
                      <given-names>R</given-names>
                    </name>
                  </person-group>
                  <article-title>Pharmacological interventions for hypertension in children</article-title>
                  <source>Cochrane Database Syst Rev.</source>
                  <year>2014</year>
                  <volume>2</volume>
                  <?supplied-pmid 24488616?>
                  <pub-id pub-id-type="pmid">24488616</pub-id>
                </element-citation>
              </ref>
              <ref id="CR10">
                <label>10.</label>
                <mixed-citation publication-type="other">National High Blood Pressure Education Program Working Group on High Blood Pressure in Children and Adolescents. The fourth report on the diagnosis, evaluation, and treatment of high blood pressure in children and adolescents. Pediatrics. 2004;114(2 Suppl 4th Report):555–76.</mixed-citation>
              </ref>
              <ref id="CR11">
                <label>11.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Batisky</surname>
                      <given-names>DL</given-names>
                    </name>
                  </person-group>
                  <article-title>What is the optimal first-line agent in children requiring antihypertensive medication?</article-title>
                  <source>Curr Hypertens Rep</source>
                  <year>2012</year>
                  <volume>14</volume>
                  <issue>6</issue>
                  <fpage>603</fpage>
                  <lpage>7</lpage>
                  <pub-id pub-id-type="doi">10.1007/s11906-012-0302-7</pub-id>
                  <?supplied-pmid 22986908?>
                  <pub-id pub-id-type="pmid">22986908</pub-id>
                </element-citation>
              </ref>
              <ref id="CR12">
                <label>12.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Yoon</surname>
                      <given-names>EY</given-names>
                    </name>
                    <name>
                      <surname>Davis</surname>
                      <given-names>MM</given-names>
                    </name>
                    <name>
                      <surname>Rocchini</surname>
                      <given-names>A</given-names>
                    </name>
                    <name>
                      <surname>Kershaw</surname>
                      <given-names>D</given-names>
                    </name>
                    <name>
                      <surname>Freed</surname>
                      <given-names>GL</given-names>
                    </name>
                  </person-group>
                  <article-title>Medical management of children with primary hypertension by pediatric subspecialists</article-title>
                  <source>Pediatr Nephrol</source>
                  <year>2009</year>
                  <volume>24</volume>
                  <issue>1</issue>
                  <fpage>147</fpage>
                  <lpage>53</lpage>
                  <pub-id pub-id-type="doi">10.1007/s00467-008-0970-3</pub-id>
                  <?supplied-pmid 18781337?>
                  <pub-id pub-id-type="pmid">18781337</pub-id>
                </element-citation>
              </ref>
              <ref id="CR13">
                <label>13.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Yoon</surname>
                      <given-names>EY</given-names>
                    </name>
                    <name>
                      <surname>Cohn</surname>
                      <given-names>L</given-names>
                    </name>
                    <name>
                      <surname>Rocchini</surname>
                      <given-names>A</given-names>
                    </name>
                    <name>
                      <surname>Kershaw</surname>
                      <given-names>D</given-names>
                    </name>
                    <name>
                      <surname>Freed</surname>
                      <given-names>G</given-names>
                    </name>
                    <name>
                      <surname>Ascione</surname>
                      <given-names>F</given-names>
                    </name>
                    <etal/>
                  </person-group>
                  <article-title>Antihypertensive prescribing patterns for adolescents with primary hypertension</article-title>
                  <source>Pediatrics</source>
                  <year>2012</year>
                  <volume>129</volume>
                  <issue>1</issue>
                  <fpage>e1</fpage>
                  <lpage>8</lpage>
                  <pub-id pub-id-type="doi">10.1542/peds.2011-0877</pub-id>
                  <?supplied-pmid 22144698?>
                  <pub-id pub-id-type="pmid">22144698</pub-id>
                </element-citation>
              </ref>
              <ref id="CR14">
                <label>14.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Woroniecki</surname>
                      <given-names>RP</given-names>
                    </name>
                    <name>
                      <surname>Flynn</surname>
                      <given-names>JT</given-names>
                    </name>
                  </person-group>
                  <article-title>How are hypertensive children evaluated and managed? A survey of North American pediatric nephrologists</article-title>
                  <source>Pediatr Nephrol</source>
                  <year>2005</year>
                  <volume>20</volume>
                  <issue>6</issue>
                  <fpage>791</fpage>
                  <lpage>7</lpage>
                  <pub-id pub-id-type="doi">10.1007/s00467-004-1804-6</pub-id>
                  <?supplied-pmid 15809834?>
                  <pub-id pub-id-type="pmid">15809834</pub-id>
                </element-citation>
              </ref>
              <ref id="CR15">
                <label>15.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Kent</surname>
                      <given-names>DM</given-names>
                    </name>
                    <name>
                      <surname>Hayward</surname>
                      <given-names>RA</given-names>
                    </name>
                  </person-group>
                  <article-title>Limitations of applying summary results of clinical trials to individual patients: the need for risk stratification</article-title>
                  <source>JAMA</source>
                  <year>2007</year>
                  <volume>298</volume>
                  <issue>10</issue>
                  <fpage>1209</fpage>
                  <lpage>12</lpage>
                  <pub-id pub-id-type="doi">10.1001/jama.298.10.1209</pub-id>
                  <?supplied-pmid 17848656?>
                  <pub-id pub-id-type="pmid">17848656</pub-id>
                </element-citation>
              </ref>
              <ref id="CR16">
                <label>16.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Sun</surname>
                      <given-names>X</given-names>
                    </name>
                    <name>
                      <surname>Ioannidis</surname>
                      <given-names>JP</given-names>
                    </name>
                    <name>
                      <surname>Agoritsas</surname>
                      <given-names>T</given-names>
                    </name>
                    <name>
                      <surname>Alba</surname>
                      <given-names>AC</given-names>
                    </name>
                    <name>
                      <surname>Guyatt</surname>
                      <given-names>G</given-names>
                    </name>
                  </person-group>
                  <article-title>How to use a subgroup analysis: users’ guide to the medical literature</article-title>
                  <source>JAMA</source>
                  <year>2014</year>
                  <volume>311</volume>
                  <issue>4</issue>
                  <fpage>405</fpage>
                  <lpage>11</lpage>
                  <pub-id pub-id-type="doi">10.1001/jama.2013.285063</pub-id>
                  <?supplied-pmid 24449319?>
                  <pub-id pub-id-type="pmid">24449319</pub-id>
                </element-citation>
              </ref>
              <ref id="CR17">
                <label>17.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Kraemer</surname>
                      <given-names>HC</given-names>
                    </name>
                    <name>
                      <surname>Frank</surname>
                      <given-names>E</given-names>
                    </name>
                    <name>
                      <surname>Kupfer</surname>
                      <given-names>DJ</given-names>
                    </name>
                  </person-group>
                  <article-title>Moderators of treatment outcomes: clinical, research, and policy importance</article-title>
                  <source>JAMA</source>
                  <year>2006</year>
                  <volume>296</volume>
                  <issue>10</issue>
                  <fpage>1286</fpage>
                  <lpage>9</lpage>
                  <pub-id pub-id-type="doi">10.1001/jama.296.10.1286</pub-id>
                  <?supplied-pmid 16968853?>
                  <pub-id pub-id-type="pmid">16968853</pub-id>
                </element-citation>
              </ref>
              <ref id="CR18">
                <label>18.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Duan</surname>
                      <given-names>N</given-names>
                    </name>
                    <name>
                      <surname>Kravitz</surname>
                      <given-names>RL</given-names>
                    </name>
                    <name>
                      <surname>Schmid</surname>
                      <given-names>CH</given-names>
                    </name>
                  </person-group>
                  <article-title>Single-patient (n-of-1) trials: a pragmatic clinical decision methodology for patient-centered comparative effectiveness research</article-title>
                  <source>J Clin Epidemiol</source>
                  <year>2013</year>
                  <volume>66</volume>
                  <issue>8 Suppl</issue>
                  <fpage>S21</fpage>
                  <lpage>8</lpage>
                  <pub-id pub-id-type="doi">10.1016/j.jclinepi.2013.04.006</pub-id>
                  <?supplied-pmid 23849149?>
                  <pub-id pub-id-type="pmid">23849149</pub-id>
                </element-citation>
              </ref>
              <ref id="CR19">
                <label>19.</label>
                <mixed-citation publication-type="other">Kravitz RL DN, the DEcIDE Methods Center N-of-1 Guidance Panel (Duan N, Eslick I,, Gabler NB KH, Kravitz RL, Larson EB, Pace WD, Schmid CH, Sim I, Vohra S). Design and implementation of N-of-1 trials: a user’s guide. Rockville, MD: Agency for Healthcare Research and Quality;2014.</mixed-citation>
              </ref>
              <ref id="CR20">
                <label>20.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Lillie</surname>
                      <given-names>EO</given-names>
                    </name>
                    <name>
                      <surname>Patay</surname>
                      <given-names>B</given-names>
                    </name>
                    <name>
                      <surname>Diamant</surname>
                      <given-names>J</given-names>
                    </name>
                    <name>
                      <surname>Issell</surname>
                      <given-names>B</given-names>
                    </name>
                    <name>
                      <surname>Topol</surname>
                      <given-names>EJ</given-names>
                    </name>
                    <name>
                      <surname>Schork</surname>
                      <given-names>NJ</given-names>
                    </name>
                  </person-group>
                  <article-title>The n-of-1 clinical trial: the ultimate strategy for individualizing medicine?</article-title>
                  <source>Per Med</source>
                  <year>2011</year>
                  <volume>8</volume>
                  <issue>2</issue>
                  <fpage>161</fpage>
                  <lpage>73</lpage>
                  <pub-id pub-id-type="doi">10.2217/pme.11.7</pub-id>
                  <?supplied-pmid 21695041?>
                  <pub-id pub-id-type="pmid">21695041</pub-id>
                </element-citation>
              </ref>
              <ref id="CR21">
                <label>21.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Mulley</surname>
                      <given-names>AG</given-names>
                    </name>
                    <name>
                      <surname>Trimble</surname>
                      <given-names>C</given-names>
                    </name>
                    <name>
                      <surname>Elwyn</surname>
                      <given-names>G</given-names>
                    </name>
                  </person-group>
                  <article-title>Stop the silent misdiagnosis: patients’ preferences matter</article-title>
                  <source>BMJ.</source>
                  <year>2012</year>
                  <volume>345</volume>
                  <pub-id pub-id-type="doi">10.1136/bmj.e6572</pub-id>
                  <?supplied-pmid 23137819?>
                  <pub-id pub-id-type="pmid">23137819</pub-id>
                </element-citation>
              </ref>
              <ref id="CR22">
                <label>22.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Wilson</surname>
                      <given-names>SR</given-names>
                    </name>
                    <name>
                      <surname>Strub</surname>
                      <given-names>P</given-names>
                    </name>
                    <name>
                      <surname>Buist</surname>
                      <given-names>AS</given-names>
                    </name>
                    <name>
                      <surname>Knowles</surname>
                      <given-names>SB</given-names>
                    </name>
                    <name>
                      <surname>Lavori</surname>
                      <given-names>PW</given-names>
                    </name>
                    <name>
                      <surname>Lapidus</surname>
                      <given-names>J</given-names>
                    </name>
                    <etal/>
                  </person-group>
                  <article-title>Shared treatment decision making improves adherence and outcomes in poorly controlled asthma</article-title>
                  <source>Am J Respir Crit Care Med</source>
                  <year>2010</year>
                  <volume>181</volume>
                  <issue>6</issue>
                  <fpage>566</fpage>
                  <lpage>77</lpage>
                  <pub-id pub-id-type="doi">10.1164/rccm.200906-0907OC</pub-id>
                  <?supplied-pmid 20019345?>
                  <pub-id pub-id-type="pmid">20019345</pub-id>
                </element-citation>
              </ref>
              <ref id="CR23">
                <label>23.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Greenfield</surname>
                      <given-names>S</given-names>
                    </name>
                    <name>
                      <surname>Kaplan</surname>
                      <given-names>S</given-names>
                    </name>
                    <name>
                      <surname>Ware</surname>
                      <given-names>JE</given-names>
                      <suffix>Jr</suffix>
                    </name>
                  </person-group>
                  <article-title>Expanding patient involvement in care. Effects on patient outcomes</article-title>
                  <source>Ann Intern Med</source>
                  <year>1985</year>
                  <volume>102</volume>
                  <issue>4</issue>
                  <fpage>520</fpage>
                  <lpage>8</lpage>
                  <pub-id pub-id-type="doi">10.7326/0003-4819-102-4-520</pub-id>
                  <?supplied-pmid 3977198?>
                  <pub-id pub-id-type="pmid">3977198</pub-id>
                </element-citation>
              </ref>
              <ref id="CR24">
                <label>24.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Guyatt</surname>
                      <given-names>G</given-names>
                    </name>
                    <name>
                      <surname>Sackett</surname>
                      <given-names>D</given-names>
                    </name>
                    <name>
                      <surname>Adachi</surname>
                      <given-names>J</given-names>
                    </name>
                    <name>
                      <surname>Roberts</surname>
                      <given-names>R</given-names>
                    </name>
                    <name>
                      <surname>Chong</surname>
                      <given-names>J</given-names>
                    </name>
                    <name>
                      <surname>Rosenbloom</surname>
                      <given-names>D</given-names>
                    </name>
                    <etal/>
                  </person-group>
                  <article-title>A clinician’s guide for conducting randomized trials in individual patients</article-title>
                  <source>CMAJ</source>
                  <year>1988</year>
                  <volume>139</volume>
                  <issue>6</issue>
                  <fpage>497</fpage>
                  <lpage>503</lpage>
                  <?supplied-pmid 3409138?>
                  <pub-id pub-id-type="pmid">3409138</pub-id>
                </element-citation>
              </ref>
              <ref id="CR25">
                <label>25.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Mahon</surname>
                      <given-names>JL</given-names>
                    </name>
                    <name>
                      <surname>Laupacis</surname>
                      <given-names>A</given-names>
                    </name>
                    <name>
                      <surname>Hodder</surname>
                      <given-names>RV</given-names>
                    </name>
                    <name>
                      <surname>McKim</surname>
                      <given-names>DA</given-names>
                    </name>
                    <name>
                      <surname>Paterson</surname>
                      <given-names>NA</given-names>
                    </name>
                    <name>
                      <surname>Wood</surname>
                      <given-names>TE</given-names>
                    </name>
                    <etal/>
                  </person-group>
                  <article-title>Theophylline for irreversible chronic airflow limitation: a randomized study comparing n of 1 trials to standard practice</article-title>
                  <source>Chest</source>
                  <year>1999</year>
                  <volume>115</volume>
                  <issue>1</issue>
                  <fpage>38</fpage>
                  <lpage>48</lpage>
                  <pub-id pub-id-type="doi">10.1378/chest.115.1.38</pub-id>
                  <?supplied-pmid 9925061?>
                  <pub-id pub-id-type="pmid">9925061</pub-id>
                </element-citation>
              </ref>
              <ref id="CR26">
                <label>26.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Scuffham</surname>
                      <given-names>PA</given-names>
                    </name>
                    <name>
                      <surname>Nikles</surname>
                      <given-names>J</given-names>
                    </name>
                    <name>
                      <surname>Mitchell</surname>
                      <given-names>GK</given-names>
                    </name>
                    <name>
                      <surname>Yelland</surname>
                      <given-names>MJ</given-names>
                    </name>
                    <name>
                      <surname>Vine</surname>
                      <given-names>N</given-names>
                    </name>
                    <name>
                      <surname>Poulos</surname>
                      <given-names>CJ</given-names>
                    </name>
                    <etal/>
                  </person-group>
                  <article-title>Using N-of-1 trials to improve patient management and save costs</article-title>
                  <source>J Gen Intern Med</source>
                  <year>2010</year>
                  <volume>25</volume>
                  <issue>9</issue>
                  <fpage>906</fpage>
                  <lpage>13</lpage>
                  <pub-id pub-id-type="doi">10.1007/s11606-010-1352-7</pub-id>
                  <?supplied-pmid 20386995?>
                  <pub-id pub-id-type="pmid">20386995</pub-id>
                </element-citation>
              </ref>
              <ref id="CR27">
                <label>27.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Yelland</surname>
                      <given-names>MJ</given-names>
                    </name>
                    <name>
                      <surname>Poulos</surname>
                      <given-names>CJ</given-names>
                    </name>
                    <name>
                      <surname>Pillans</surname>
                      <given-names>PI</given-names>
                    </name>
                    <name>
                      <surname>Bashford</surname>
                      <given-names>GM</given-names>
                    </name>
                    <name>
                      <surname>Nikles</surname>
                      <given-names>CJ</given-names>
                    </name>
                    <name>
                      <surname>Sturtevant</surname>
                      <given-names>JM</given-names>
                    </name>
                    <etal/>
                  </person-group>
                  <article-title>N-of-1 randomized trials to assess the efficacy of gabapentin for chronic neuropathic pain</article-title>
                  <source>Pain Med</source>
                  <year>2009</year>
                  <volume>10</volume>
                  <issue>4</issue>
                  <fpage>754</fpage>
                  <lpage>61</lpage>
                  <pub-id pub-id-type="doi">10.1111/j.1526-4637.2009.00615.x</pub-id>
                  <?supplied-pmid 19453961?>
                  <pub-id pub-id-type="pmid">19453961</pub-id>
                </element-citation>
              </ref>
              <ref id="CR28">
                <label>28.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Gabler</surname>
                      <given-names>NB</given-names>
                    </name>
                    <name>
                      <surname>Duan</surname>
                      <given-names>N</given-names>
                    </name>
                    <name>
                      <surname>Vohra</surname>
                      <given-names>S</given-names>
                    </name>
                    <name>
                      <surname>Kravitz</surname>
                      <given-names>RL</given-names>
                    </name>
                  </person-group>
                  <article-title>N-of-1 trials in the medical literature: a systematic review</article-title>
                  <source>Med Care</source>
                  <year>2011</year>
                  <volume>49</volume>
                  <issue>8</issue>
                  <fpage>761</fpage>
                  <lpage>8</lpage>
                  <pub-id pub-id-type="doi">10.1097/MLR.0b013e318215d90d</pub-id>
                  <?supplied-pmid 21478771?>
                  <pub-id pub-id-type="pmid">21478771</pub-id>
                </element-citation>
              </ref>
              <ref id="CR29">
                <label>29.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Senior</surname>
                      <given-names>HE</given-names>
                    </name>
                    <name>
                      <surname>Mitchell</surname>
                      <given-names>GK</given-names>
                    </name>
                    <name>
                      <surname>Nikles</surname>
                      <given-names>J</given-names>
                    </name>
                    <name>
                      <surname>Carmont</surname>
                      <given-names>SA</given-names>
                    </name>
                    <name>
                      <surname>Schluter</surname>
                      <given-names>PJ</given-names>
                    </name>
                    <name>
                      <surname>Currow</surname>
                      <given-names>DC</given-names>
                    </name>
                    <etal/>
                  </person-group>
                  <article-title>Using aggregated single patient (N-of-1) trials to determine the effectiveness of psychostimulants to reduce fatigue in advanced cancer patients: a rationale and protocol</article-title>
                  <source>BMC Palliat Care</source>
                  <year>2013</year>
                  <volume>12</volume>
                  <issue>1</issue>
                  <fpage>17</fpage>
                  <pub-id pub-id-type="doi">10.1186/1472-684X-12-17</pub-id>
                  <?supplied-pmid 23617794?>
                  <pub-id pub-id-type="pmid">23617794</pub-id>
                </element-citation>
              </ref>
              <ref id="CR30">
                <label>30.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Nikles</surname>
                      <given-names>CJ</given-names>
                    </name>
                    <name>
                      <surname>McKinlay</surname>
                      <given-names>L</given-names>
                    </name>
                    <name>
                      <surname>Mitchell</surname>
                      <given-names>GK</given-names>
                    </name>
                    <name>
                      <surname>Carmont</surname>
                      <given-names>SA</given-names>
                    </name>
                    <name>
                      <surname>Senior</surname>
                      <given-names>HE</given-names>
                    </name>
                    <name>
                      <surname>Waugh</surname>
                      <given-names>MC</given-names>
                    </name>
                    <etal/>
                  </person-group>
                  <article-title>Aggregated n-of-1 trials of central nervous system stimulants versus placebo for paediatric traumatic brain injury--a pilot study</article-title>
                  <source>Trials.</source>
                  <year>2014</year>
                  <volume>15</volume>
                  <fpage>54</fpage>
                  <pub-id pub-id-type="doi">10.1186/1745-6215-15-54</pub-id>
                  <?supplied-pmid 24524676?>
                  <pub-id pub-id-type="pmid">24524676</pub-id>
                </element-citation>
              </ref>
              <ref id="CR31">
                <label>31.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Flynn</surname>
                      <given-names>JT</given-names>
                    </name>
                    <name>
                      <surname>Newburger</surname>
                      <given-names>JW</given-names>
                    </name>
                    <name>
                      <surname>Daniels</surname>
                      <given-names>SR</given-names>
                    </name>
                    <name>
                      <surname>Sanders</surname>
                      <given-names>SP</given-names>
                    </name>
                    <name>
                      <surname>Portman</surname>
                      <given-names>RJ</given-names>
                    </name>
                    <name>
                      <surname>Hogg</surname>
                      <given-names>RJ</given-names>
                    </name>
                    <etal/>
                  </person-group>
                  <article-title>A randomized, placebo-controlled trial of amlodipine in children with hypertension</article-title>
                  <source>J Pediatr</source>
                  <year>2004</year>
                  <volume>145</volume>
                  <issue>3</issue>
                  <fpage>353</fpage>
                  <lpage>9</lpage>
                  <pub-id pub-id-type="doi">10.1016/j.jpeds.2004.04.009</pub-id>
                  <?supplied-pmid 15343191?>
                  <pub-id pub-id-type="pmid">15343191</pub-id>
                </element-citation>
              </ref>
              <ref id="CR32">
                <label>32.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Soffer</surname>
                      <given-names>B</given-names>
                    </name>
                    <name>
                      <surname>Zhang</surname>
                      <given-names>Z</given-names>
                    </name>
                    <name>
                      <surname>Miller</surname>
                      <given-names>K</given-names>
                    </name>
                    <name>
                      <surname>Vogt</surname>
                      <given-names>BA</given-names>
                    </name>
                    <name>
                      <surname>Shahinfar</surname>
                      <given-names>S</given-names>
                    </name>
                  </person-group>
                  <article-title>A double-blind, placebo-controlled, dose-response study of the effectiveness and safety of lisinopril for children with hypertension</article-title>
                  <source>Am J Hypertens</source>
                  <year>2003</year>
                  <volume>16</volume>
                  <issue>10</issue>
                  <fpage>795</fpage>
                  <lpage>800</lpage>
                  <pub-id pub-id-type="doi">10.1016/S0895-7061(03)00900-2</pub-id>
                  <?supplied-pmid 14553956?>
                  <pub-id pub-id-type="pmid">14553956</pub-id>
                </element-citation>
              </ref>
              <ref id="CR33">
                <label>33.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Musini</surname>
                      <given-names>VM</given-names>
                    </name>
                    <name>
                      <surname>Nazer</surname>
                      <given-names>M</given-names>
                    </name>
                    <name>
                      <surname>Bassett</surname>
                      <given-names>K</given-names>
                    </name>
                    <name>
                      <surname>Wright</surname>
                      <given-names>JM</given-names>
                    </name>
                  </person-group>
                  <article-title>Blood pressure-lowering efficacy of monotherapy with thiazide diuretics for primary hypertension</article-title>
                  <source>Cochrane Database Syst Rev.</source>
                  <year>2014</year>
                  <volume>5</volume>
                  <?supplied-pmid 24869750?>
                  <pub-id pub-id-type="pmid">24869750</pub-id>
                </element-citation>
              </ref>
              <ref id="CR34">
                <label>34.</label>
                <mixed-citation publication-type="other">Haahr M. 2006. <ext-link ext-link-type="uri" xlink:href="http://www.random.org">http://www.random.org</ext-link>. Accessed: 6 June 2013.</mixed-citation>
              </ref>
              <ref id="CR35">
                <label>35.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Flynn</surname>
                      <given-names>JT</given-names>
                    </name>
                    <name>
                      <surname>Daniels</surname>
                      <given-names>SR</given-names>
                    </name>
                    <name>
                      <surname>Hayman</surname>
                      <given-names>LL</given-names>
                    </name>
                    <name>
                      <surname>Maahs</surname>
                      <given-names>DM</given-names>
                    </name>
                    <name>
                      <surname>McCrindle</surname>
                      <given-names>BW</given-names>
                    </name>
                    <name>
                      <surname>Mitsnefes</surname>
                      <given-names>M</given-names>
                    </name>
                    <etal/>
                  </person-group>
                  <article-title>Update: ambulatory blood pressure monitoring in children and adolescents: a scientific statement from the American Heart Association</article-title>
                  <source>Hypertension</source>
                  <year>2014</year>
                  <volume>63</volume>
                  <issue>5</issue>
                  <fpage>1116</fpage>
                  <lpage>35</lpage>
                  <pub-id pub-id-type="doi">10.1161/HYP.0000000000000007</pub-id>
                  <?supplied-pmid 24591341?>
                  <pub-id pub-id-type="pmid">24591341</pub-id>
                </element-citation>
              </ref>
              <ref id="CR36">
                <label>36.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Pickering</surname>
                      <given-names>TG</given-names>
                    </name>
                    <name>
                      <surname>Hall</surname>
                      <given-names>JE</given-names>
                    </name>
                    <name>
                      <surname>Appel</surname>
                      <given-names>LJ</given-names>
                    </name>
                    <name>
                      <surname>Falkner</surname>
                      <given-names>BE</given-names>
                    </name>
                    <name>
                      <surname>Graves</surname>
                      <given-names>J</given-names>
                    </name>
                    <name>
                      <surname>Hill</surname>
                      <given-names>MN</given-names>
                    </name>
                    <etal/>
                  </person-group>
                  <article-title>Recommendations for blood pressure measurement in humans and experimental animals: Part 1: blood pressure measurement in humans: a statement for professionals from the Subcommittee of Professional and Public Education of the American Heart Association Council on High Blood Pressure Research</article-title>
                  <source>Hypertension</source>
                  <year>2005</year>
                  <volume>45</volume>
                  <issue>1</issue>
                  <fpage>142</fpage>
                  <lpage>61</lpage>
                  <pub-id pub-id-type="doi">10.1161/01.HYP.0000150859.47929.8e</pub-id>
                  <?supplied-pmid 15611362?>
                  <pub-id pub-id-type="pmid">15611362</pub-id>
                </element-citation>
              </ref>
              <ref id="CR37">
                <label>37.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Beermann</surname>
                      <given-names>B</given-names>
                    </name>
                    <name>
                      <surname>Groschinsky-Grind</surname>
                      <given-names>M</given-names>
                    </name>
                  </person-group>
                  <article-title>Pharmacokinetics of hydrochlorothiazide in man</article-title>
                  <source>Eur J Clin Pharmacol</source>
                  <year>1977</year>
                  <volume>12</volume>
                  <issue>4</issue>
                  <fpage>297</fpage>
                  <lpage>303</lpage>
                  <pub-id pub-id-type="doi">10.1007/BF00607430</pub-id>
                  <?supplied-pmid 590315?>
                  <pub-id pub-id-type="pmid">590315</pub-id>
                </element-citation>
              </ref>
              <ref id="CR38">
                <label>38.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Flynn</surname>
                      <given-names>JT</given-names>
                    </name>
                    <name>
                      <surname>Nahata</surname>
                      <given-names>MC</given-names>
                    </name>
                    <name>
                      <surname>Mahan</surname>
                      <given-names>JD</given-names>
                      <suffix>Jr</suffix>
                    </name>
                    <name>
                      <surname>Portman</surname>
                      <given-names>RJ</given-names>
                    </name>
                    <collab>PATH-2 Investigators</collab>
                  </person-group>
                  <article-title>Population pharmacokinetics of amlodipine in hypertensive children and adolescents</article-title>
                  <source>J Clin Pharmacol</source>
                  <year>2006</year>
                  <volume>46</volume>
                  <issue>8</issue>
                  <fpage>905</fpage>
                  <lpage>16</lpage>
                  <pub-id pub-id-type="doi">10.1177/0091270006289844</pub-id>
                  <?supplied-pmid 16855075?>
                  <pub-id pub-id-type="pmid">16855075</pub-id>
                </element-citation>
              </ref>
              <ref id="CR39">
                <label>39.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Hogg</surname>
                      <given-names>RJ</given-names>
                    </name>
                    <name>
                      <surname>Delucchi</surname>
                      <given-names>A</given-names>
                    </name>
                    <name>
                      <surname>Sakihara</surname>
                      <given-names>G</given-names>
                    </name>
                    <name>
                      <surname>Wells</surname>
                      <given-names>TG</given-names>
                    </name>
                    <name>
                      <surname>Tenney</surname>
                      <given-names>F</given-names>
                    </name>
                    <name>
                      <surname>Batisky</surname>
                      <given-names>DL</given-names>
                    </name>
                    <etal/>
                  </person-group>
                  <article-title>A multicenter study of the pharmacokinetics of lisinopril in pediatric patients with hypertension</article-title>
                  <source>Pediatr Nephrol</source>
                  <year>2007</year>
                  <volume>22</volume>
                  <issue>5</issue>
                  <fpage>695</fpage>
                  <lpage>701</lpage>
                  <pub-id pub-id-type="doi">10.1007/s00467-006-0399-5</pub-id>
                  <?supplied-pmid 17216247?>
                  <pub-id pub-id-type="pmid">17216247</pub-id>
                </element-citation>
              </ref>
              <ref id="CR40">
                <label>40.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Alpert</surname>
                      <given-names>BS</given-names>
                    </name>
                  </person-group>
                  <article-title>Validation of the Welch Allyn Spot Vital Signs blood pressure device according to the ANSI/AAMI SP10: 2002. Accuracy and cost-efficiency successfully combined</article-title>
                  <source>Blood Press Monit</source>
                  <year>2007</year>
                  <volume>12</volume>
                  <issue>5</issue>
                  <fpage>345</fpage>
                  <lpage>7</lpage>
                  <pub-id pub-id-type="doi">10.1097/MBP.0b013e3282c9abf7</pub-id>
                  <?supplied-pmid 17890975?>
                  <pub-id pub-id-type="pmid">17890975</pub-id>
                </element-citation>
              </ref>
              <ref id="CR41">
                <label>41.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Gimpel</surname>
                      <given-names>C</given-names>
                    </name>
                    <name>
                      <surname>Wühl</surname>
                      <given-names>E</given-names>
                    </name>
                    <name>
                      <surname>Arbeiter</surname>
                      <given-names>K</given-names>
                    </name>
                    <name>
                      <surname>Drozdz</surname>
                      <given-names>D</given-names>
                    </name>
                    <name>
                      <surname>Trivelli</surname>
                      <given-names>A</given-names>
                    </name>
                    <name>
                      <surname>Charbit</surname>
                      <given-names>M</given-names>
                    </name>
                    <etal/>
                  </person-group>
                  <article-title>Superior consistency of ambulatory blood pressure monitoring in children: implications for clinical trials</article-title>
                  <source>J Hypertens</source>
                  <year>2009</year>
                  <volume>27</volume>
                  <issue>8</issue>
                  <fpage>1568</fpage>
                  <lpage>74</lpage>
                  <pub-id pub-id-type="doi">10.1097/HJH.0b013e32832cb2a8</pub-id>
                  <?supplied-pmid 19550356?>
                  <pub-id pub-id-type="pmid">19550356</pub-id>
                </element-citation>
              </ref>
              <ref id="CR42">
                <label>42.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Barnes</surname>
                      <given-names>VA</given-names>
                    </name>
                    <name>
                      <surname>Johnson</surname>
                      <given-names>MH</given-names>
                    </name>
                    <name>
                      <surname>Dekkers</surname>
                      <given-names>JC</given-names>
                    </name>
                    <name>
                      <surname>Treiber</surname>
                      <given-names>FA</given-names>
                    </name>
                  </person-group>
                  <article-title>Reproducibility of ambulatory blood pressure measures in African-American adolescents</article-title>
                  <source>Ethn Dis</source>
                  <year>2002</year>
                  <volume>12</volume>
                  <issue>4</issue>
                  <fpage>S3-101-6</fpage>
                  <?supplied-pmid 12477164?>
                  <pub-id pub-id-type="pmid">12477164</pub-id>
                </element-citation>
              </ref>
              <ref id="CR43">
                <label>43.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Krmar</surname>
                      <given-names>RT</given-names>
                    </name>
                    <name>
                      <surname>Berg</surname>
                      <given-names>UB</given-names>
                    </name>
                  </person-group>
                  <article-title>Long-term reproducibility of routine ambulatory blood pressure monitoring in stable pediatric renal transplant recipients</article-title>
                  <source>Am J Hypertens</source>
                  <year>2005</year>
                  <volume>18</volume>
                  <issue>11</issue>
                  <fpage>1408</fpage>
                  <lpage>14</lpage>
                  <pub-id pub-id-type="doi">10.1016/j.amjhyper.2005.05.018</pub-id>
                  <?supplied-pmid 16280272?>
                  <pub-id pub-id-type="pmid">16280272</pub-id>
                </element-citation>
              </ref>
              <ref id="CR44">
                <label>44.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Lurbe</surname>
                      <given-names>E</given-names>
                    </name>
                    <name>
                      <surname>Redon</surname>
                      <given-names>J</given-names>
                    </name>
                  </person-group>
                  <article-title>Reproducibility and validity of ambulatory blood pressure monitoring in children</article-title>
                  <source>Am J Hypertens</source>
                  <year>2002</year>
                  <volume>15</volume>
                  <issue>2 Pt 2</issue>
                  <fpage>69S</fpage>
                  <lpage>73S</lpage>
                  <pub-id pub-id-type="doi">10.1016/S0895-7061(01)02300-7</pub-id>
                  <?supplied-pmid 11866236?>
                  <pub-id pub-id-type="pmid">11866236</pub-id>
                </element-citation>
              </ref>
              <ref id="CR45">
                <label>45.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Stergiou</surname>
                      <given-names>GS</given-names>
                    </name>
                    <name>
                      <surname>Alamara</surname>
                      <given-names>CV</given-names>
                    </name>
                    <name>
                      <surname>Salgami</surname>
                      <given-names>EV</given-names>
                    </name>
                    <name>
                      <surname>Vaindirlis</surname>
                      <given-names>IN</given-names>
                    </name>
                    <name>
                      <surname>Dacou-Voutetakis</surname>
                      <given-names>C</given-names>
                    </name>
                    <name>
                      <surname>Mountokalakis</surname>
                      <given-names>TD</given-names>
                    </name>
                  </person-group>
                  <article-title>Reproducibility of home and ambulatory blood pressure in children and adolescents</article-title>
                  <source>Blood Press Monit</source>
                  <year>2005</year>
                  <volume>10</volume>
                  <issue>3</issue>
                  <fpage>143</fpage>
                  <lpage>7</lpage>
                  <pub-id pub-id-type="doi">10.1097/00126097-200506000-00005</pub-id>
                  <?supplied-pmid 15923815?>
                  <pub-id pub-id-type="pmid">15923815</pub-id>
                </element-citation>
              </ref>
              <ref id="CR46">
                <label>46.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Agarwal</surname>
                      <given-names>R</given-names>
                    </name>
                    <name>
                      <surname>Weir</surname>
                      <given-names>MR</given-names>
                    </name>
                  </person-group>
                  <article-title>Treated hypertension and the white coat phenomenon: office readings are inadequate measures of efficacy</article-title>
                  <source>J Am Soc Hypertens</source>
                  <year>2013</year>
                  <volume>7</volume>
                  <issue>3</issue>
                  <fpage>236</fpage>
                  <lpage>43</lpage>
                  <pub-id pub-id-type="doi">10.1016/j.jash.2013.02.005</pub-id>
                  <?supplied-pmid 23523137?>
                  <pub-id pub-id-type="pmid">23523137</pub-id>
                </element-citation>
              </ref>
              <ref id="CR47">
                <label>47.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Gorostidi</surname>
                      <given-names>M</given-names>
                    </name>
                    <name>
                      <surname>Sarafidis</surname>
                      <given-names>PA</given-names>
                    </name>
                    <name>
                      <surname>de la Sierra</surname>
                      <given-names>A</given-names>
                    </name>
                    <name>
                      <surname>Segura</surname>
                      <given-names>J</given-names>
                    </name>
                    <name>
                      <surname>de la Cruz</surname>
                      <given-names>JJ</given-names>
                    </name>
                    <name>
                      <surname>Banegas</surname>
                      <given-names>JR</given-names>
                    </name>
                    <etal/>
                  </person-group>
                  <article-title>Differences between office and 24-h blood pressure control in hypertensive patients with CKD: a 5,693-patient cross-sectional analysis from Spain</article-title>
                  <source>Am J Kidney Dis</source>
                  <year>2013</year>
                  <volume>62</volume>
                  <issue>2</issue>
                  <fpage>285</fpage>
                  <lpage>94</lpage>
                  <pub-id pub-id-type="doi">10.1053/j.ajkd.2013.03.025</pub-id>
                  <?supplied-pmid 23689071?>
                  <pub-id pub-id-type="pmid">23689071</pub-id>
                </element-citation>
              </ref>
              <ref id="CR48">
                <label>48.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Parati</surname>
                      <given-names>G</given-names>
                    </name>
                    <name>
                      <surname>Ravogli</surname>
                      <given-names>A</given-names>
                    </name>
                    <name>
                      <surname>Mutti</surname>
                      <given-names>E</given-names>
                    </name>
                    <name>
                      <surname>Santucciu</surname>
                      <given-names>C</given-names>
                    </name>
                    <name>
                      <surname>Omboni</surname>
                      <given-names>S</given-names>
                    </name>
                    <name>
                      <surname>Mancia</surname>
                      <given-names>G</given-names>
                    </name>
                  </person-group>
                  <article-title>Ambulatory blood pressure monitoring in the evaluation of antihypertensive drugs</article-title>
                  <source>J Hypertens Suppl</source>
                  <year>1994</year>
                  <volume>12</volume>
                  <issue>8</issue>
                  <fpage>S9</fpage>
                  <lpage>15</lpage>
                  <?supplied-pmid 7707163?>
                  <pub-id pub-id-type="pmid">7707163</pub-id>
                </element-citation>
              </ref>
              <ref id="CR49">
                <label>49.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Neutel</surname>
                      <given-names>JM</given-names>
                    </name>
                    <name>
                      <surname>Smith</surname>
                      <given-names>DH</given-names>
                    </name>
                    <name>
                      <surname>Ram</surname>
                      <given-names>CV</given-names>
                    </name>
                    <name>
                      <surname>Kaplan</surname>
                      <given-names>NM</given-names>
                    </name>
                    <name>
                      <surname>Papademetriou</surname>
                      <given-names>V</given-names>
                    </name>
                    <name>
                      <surname>Fagan</surname>
                      <given-names>TC</given-names>
                    </name>
                    <etal/>
                  </person-group>
                  <article-title>Application of ambulatory blood pressure monitoring in differentiating between antihypertensive agents</article-title>
                  <source>Am J Med</source>
                  <year>1993</year>
                  <volume>94</volume>
                  <issue>2</issue>
                  <fpage>181</fpage>
                  <lpage>7</lpage>
                  <pub-id pub-id-type="doi">10.1016/0002-9343(93)90181-N</pub-id>
                  <?supplied-pmid 8430713?>
                  <pub-id pub-id-type="pmid">8430713</pub-id>
                </element-citation>
              </ref>
              <ref id="CR50">
                <label>50.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Neutel</surname>
                      <given-names>JM</given-names>
                    </name>
                    <name>
                      <surname>Smith</surname>
                      <given-names>DH</given-names>
                    </name>
                    <name>
                      <surname>Ram</surname>
                      <given-names>CV</given-names>
                    </name>
                    <name>
                      <surname>Lefkowitz</surname>
                      <given-names>MP</given-names>
                    </name>
                    <name>
                      <surname>Kazempour</surname>
                      <given-names>MK</given-names>
                    </name>
                    <name>
                      <surname>Weber</surname>
                      <given-names>MA</given-names>
                    </name>
                  </person-group>
                  <article-title>Comparison of bisoprolol with atenolol for systemic hypertension in four population groups (young, old, black and nonblack) using ambulatory blood pressure monitoring. Bisoprolol Investigators Group</article-title>
                  <source>Am J Cardiol.</source>
                  <year>1993</year>
                  <volume>72</volume>
                  <issue>1</issue>
                  <fpage>41</fpage>
                  <lpage>6</lpage>
                  <pub-id pub-id-type="doi">10.1016/0002-9149(93)90216-Y</pub-id>
                  <?supplied-pmid 8517426?>
                  <pub-id pub-id-type="pmid">8517426</pub-id>
                </element-citation>
              </ref>
              <ref id="CR51">
                <label>51.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Mansoor</surname>
                      <given-names>GA</given-names>
                    </name>
                  </person-group>
                  <article-title>Ambulatory blood pressure monitoring in clinical trials in adults and children</article-title>
                  <source>Am J Hypertens</source>
                  <year>2002</year>
                  <volume>15</volume>
                  <issue>2 Pt 2</issue>
                  <fpage>38S</fpage>
                  <lpage>42S</lpage>
                  <pub-id pub-id-type="doi">10.1016/S0895-7061(01)02295-6</pub-id>
                  <?supplied-pmid 11866227?>
                  <pub-id pub-id-type="pmid">11866227</pub-id>
                </element-citation>
              </ref>
              <ref id="CR52">
                <label>52.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Harris</surname>
                      <given-names>PA</given-names>
                    </name>
                    <name>
                      <surname>Taylor</surname>
                      <given-names>R</given-names>
                    </name>
                    <name>
                      <surname>Thielke</surname>
                      <given-names>R</given-names>
                    </name>
                    <name>
                      <surname>Payne</surname>
                      <given-names>J</given-names>
                    </name>
                    <name>
                      <surname>Gonzalez</surname>
                      <given-names>N</given-names>
                    </name>
                    <name>
                      <surname>Conde</surname>
                      <given-names>JG</given-names>
                    </name>
                  </person-group>
                  <article-title>Research electronic data capture (REDCap)--a metadata-driven methodology and workflow process for providing translational research informatics support</article-title>
                  <source>J Biomed Inform</source>
                  <year>2009</year>
                  <volume>42</volume>
                  <issue>2</issue>
                  <fpage>377</fpage>
                  <lpage>81</lpage>
                  <pub-id pub-id-type="doi">10.1016/j.jbi.2008.08.010</pub-id>
                  <?supplied-pmid 18929686?>
                  <pub-id pub-id-type="pmid">18929686</pub-id>
                </element-citation>
              </ref>
              <ref id="CR53">
                <label>53.</label>
                <mixed-citation publication-type="other">Punja S, Eslick I, Duan N, Panel tDMCN-o-G. An Ethical Framework for N-of-1 Trials: Clinical Care, Quality Improvement, or Human Subjects Resarch? Rockville, MD: Agency for Healthcare Research and Quality; 2014. Contract No.: Chapter 2.</mixed-citation>
              </ref>
              <ref id="CR54">
                <label>54.</label>
                <mixed-citation publication-type="other">Faden RR, Kass NE, Goodman SN, Pronovost P, Tunis S, Beauchamp TL. An ethics framework for a learning health care system: a departure from traditional research ethics and clinical ethics. The Hastings Center report. 2013;Spec No:S16-27. doi:10.1002/hast.134.</mixed-citation>
              </ref>
              <ref id="CR55">
                <label>55.</label>
                <mixed-citation publication-type="other">Kass NE, Faden RR, Goodman SN, Pronovost P, Tunis S, Beauchamp TL. The research-treatment distinction: a problematic approach for determining which activities should have ethical oversight. The Hastings Center report. 2013;Spec No:S4-S15. doi:10.1002/hast.133.</mixed-citation>
              </ref>
              <ref id="CR56">
                <label>56.</label>
                <mixed-citation publication-type="other">Shamseer L, Sampson M, Bukutu C, Schmid CH, Nikles J, Tate R et al. CONSORT extension for reporting N-of-1 trials (CENT) 2015: explanation and elaboration. J Clin Epidemiol. 2015. doi:10.1016/j.jclinepi.2015.05.018.</mixed-citation>
              </ref>
            </ref-list>
          </back>
        </article>
      </metadata>
    </record>
  </GetRecord>
</OAI-PMH>
